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Introduction
Predicting who will or will not respond to a particular treat-
ment is a priority for the development of more personalized 
interventions in mental health. Functional neuroimaging 
measures may help achieve this goal.1 For example, greater 
activity at baseline in the anterior insula or anterior cingu-
late cortex (ACC), measured with 18F-fluorodeoxyglucose 
positron emission tomography (FDG-PET), has been associ-
ated with a positive outcome from antidepressant medica-
tion in patients with major depressive disorder.2,3 In the 
present study we tested whether resting-state functional 
connectivity (rs-fc) between the basolateral amygdala (BLA) 
and ventromedial prefrontal cortex (vmPFC) could predict 
outcome from cognitive behavioural therapy (CBT) in pa-
tients with obsessive–compulsive disorder (OCD).
Cognitive behavioural therapy, including exposure 
and ritual prevention, is a first-line treatment for OCD, 
but some patients do not respond or respond only par-
tially to CBT.4 There have been several attempts to cor-
relate functional neuro imaging measures and CBT out-
comes in patients with OCD.1,5 Initial studies focused on 
cortico–striato–thalamo–cortical regions believed to be 
involved in the pathophysiology of OCD, such as the 
 orbitofrontal cortex (OFC). Indeed, findings from studies 
using FDG-PET or single-photon emission computed 
 tomography (SPECT) suggest that greater baseline OFC 
activity in patients with OCD is associated with a posi-
tive outcome from CBT. However, findings from func-
tional MRI (fMRI) studies do not consistently show that 
pretreatment frontal or striatal activation is associated 
with CBT outcome.1
Newer conceptualizations emphasize the contribution 
of the amygdala and vmPFC in OCD pathophysiology 
and treatment.6 Both regions are involved in fear process-
ing and regulation, and both play a role in extinction 
Correspondence to: M.A. Fullana, Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Passeig Marítim, 25/29, 08003 Barcelona, 
Spain; miguelangelfullana@gmail.com
*Share first authorship; †share senior authorship.
Submitted Nov. 7, 2016; Revised Mar. 24, 2017; Accepted Apr. 18, 2017; Early-released June 20, 2017
DOI: 10.1503/jpn.160215
Background: Cognitive behavioural therapy (CBT), including exposure and ritual prevention, is a first-line treatment for obsessive– 
compulsive disorder (OCD), but few reliable predictors of CBT outcome have been identified. Based on research in animal models, we 
hypothesized that individual differences in basolateral amygdala–ventromedial prefrontal cortex (BLA–vmPFC) communication would 
predict CBT outcome in patients with OCD. Methods: We investigated whether BLA–vmPFC resting-state functional connectivity (rs-fc) 
predicts CBT outcome in patients with OCD. We assessed BLA–vmPFC rs-fc in patients with OCD on a stable dose of a selective sero-
tonin reuptake inhibitor who then received CBT and in healthy control participants. Results: We included 73 patients with OCD and 
84 healthy controls in our study. Decreased BLA–vmPFC rs-fc predicted a better CBT outcome in patients with OCD and was also de-
tected in those with OCD compared with healthy participants. Additional analy ses revealed that decreased BLA–vmPFC rs-fc uniquely 
characterized the patients with OCD who responded to CBT. Limitations: We used a sample of convenience, and all patients were re-
ceiving pharmacological treatment for OCD. Conclusion: In this large sample of patients with OCD, BLA–vmPFC functional connectivity 
predicted CBT outcome. These results suggest that future research should investigate the potential of BLA–vmPFC pathways to inform 
treatment selection for CBT across patients with OCD and anxiety disorders.
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learning, a likely mech anism of action in CBT for fear- 
related disorders, including OCD.7 The amygdala con-
sists of several functionally distinct nuclei, with 2 broad 
subdivisions: the BLA and the centromedial amygdala 
(CMA). Although both are involved in fear processing, 
animal studies suggest that the BLA has a more prom-
inent role in fear learning (including fear conditioning 
and extinction) and that the CMA has a more prominent 
role in fear expression.8 In healthy humans, rs-fc of these 
2 regions differ: spontaneous BLA activity correlates with 
activity in temporal and frontal cortical regions (includ-
ing the vmPFC), whereas spontaneous CMA activity cor-
relates with activity in the striatum.9 The vmPFC is asso-
ciated with different emotional and cognitive processes, 
and this complex role is likely supported by its connec-
tivity with various regions (e.g., striatum, amygdala).10 
Data from animals and humans suggest that vmPFC con-
nections with the amygdala form a network important 
for regulating stress and aversive responses. More specif-
ically, the vmPFC seems to exert inhibitory control over 
BLA activation, thereby modulating its response to aver-
sive stimuli.11
Dynamic communication between the BLA and vmPFC 
has been proposed as a key cross-species mechanism in 
adaptive learning, with deficient communication across 
regions resulting in maladaptive learning and fear gener-
alization.12 Thus, individual differences in the functioning 
of the BLA–vmPFC circuit may predict the outcome of 
learning-based treatments such as CBT. However, little re-
search has focused on connectivity within this specific cir-
cuit. Using rs-fc and an exploratory whole-brain ap-
proach, a recent study in patients with OCD found that 
the degree centrality (a generally accepted marker of 
functional connectivity) in the right BLA was positively 
associated with CBT outcome.13 That study, however, did 
not assess connectivity at the network level (i.e., it did not 
provide information about con nectivity between the BLA 
and frontal regions). Moreover, it used a small sample 
(n = 17) and studied only inpatients with OCD, thus limit-
ing the generalizability of the findings. Another study in 
patients with social anxiety disorder (SAD) found that rs-
fc between the right amygdala and the pre genual anterior 
cingulate cortex (pgACC) and between the left amygdala 
and the pgACC/medial prefrontal cortex was positively 
associated with CBT outcome.14 That study also used a 
small sample (n = 21) and did not assess connectivity 
from amygdalar subregions. Moreover, no control group 
was included, precluding the assessment of baseline 
abnormal ities in rs-fc.
Capitalizing on a large sample of patients with OCD who 
were receiving a stable dose of a selective serotonin reup-
take inhibitor (SSRI) and who then received CBT, we tested 
the hypothesis that BLA–vmPFC rs-fc would predict CBT 
outcome. In exploratory analyses, we tested whether these 
findings would be specific to BLA–vmPFC (rather than 
other amygdala–prefrontal cortex circuits) and whether 
BLA–vmPFC rs-fc would differ between patients with OCD 
and healthy control participants.
Methods
Participants
We recruited patients from the obsessive– compulsive disor-
ders unit of the University Hospital of Bellvitge, Barcelona, 
Spain. We recruited healthy controls (group-matched by 
age, sex and years of education) in the local community 
through advertisements and word of mouth. All partici-
pants provided written informed consent after receiving a 
complete description of our study protocol, which was ap-
proved by the Institutional Review Board of the University 
Hospital of Bellvitge.
Eligible patients were adults with a principal diagnosis of 
OCD (≥ 1 year) who were enrolled in our unit for an open 
12-week pharmacological trial with an SSRI (clomipramine, 
fluoxetine, fluvoxamine, or escitalopram). Patients were eli-
gible for CBT and this fMRI study if they did not respond 
(Yale–Brown Obsessive Compulsive Scale [YBOCS] reduction 
< 25%) or showed only partial response (YBOCS reduction 
< 35%)15 after at least 12 weeks of a stable dose of the SSRI, fol-
lowing recommended guidelines.16 None had previously re-
ceived CBT. The time between the end of the pharmacological 
trial and the initiation of CBT ranged between 1 and 2 weeks; 
the fMRI data were collected during this 1–2 week interval. 
Concomitant psychotropic medications were not permitted 
(except benzodiazepines if used only for sleep).
Exclusion criteria for all participants were substance use, 
abuse or dependence; psychotic or bipolar disorders; mental 
retardation; presence or history of serious medical or neuro-
logic disorder (except tic disorder); or any contraindication to 
MRI scanning. Patients with OCD who had comorbid non-
psychotic mood and anxiety disorders were included, pro-
vided that OCD was the principal and most severe diagnosis.
Psychiatric diagnoses in the OCD group were established 
independently by 2 psychiatrists (P.A. and C.S.) using the 
Structured Clinical Interview for DSM-IV Axis I Disorders 
(SCID-IV), Clinician Version.17 To be included in the healthy 
control group, participants had to have no lifetime Axis I dis-
orders, as established by a psychiatrist (E.R. or M.S.) using 
the SCID-IV, Non-patient Edition.18
Data from the same OCD and control samples were in-
cluded in a previous study of structural MRI predictors of 
CBT outcome, including cortical thickness.19
Neuroimaging data acquisition, preprocessing and analyses
Image acquisition
Participants were scanned on a 1.5 T scanner (Signa Excite 
system; General Electric) equipped with an 8-channel 
phased-array head coil. The functional sequence consisted of 
gradient recalled acquisition with the following parameters: 
repetition time (TR) 2000 ms, echo time (TE) 50 ms, flip angle 
90°, field of view (FOV) 24 cm, with a 64 × 64 pixel matrix 
and a slice thickness of 4 mm. Twenty-two interleaved sec-
tions, parallel to the anterior–posterior commissure line, were 
acquired to generate 120 whole brain volumes, excluding 4 in-
itial dummy volumes (total scan time 4 minutes). Participants 
Fullana et al.
380 J Psychiatry Neurosci 2017;42(6)
were instructed to relax, stay awake and to lie still while 
keeping their eyes closed throughout the scan. A high- 
resolution T1-weighted anatomic image was also obtained 
from each participant using a 3-dimensional fast spoiled gra-
dient inversion-recovery prepared sequence with 130 con-
tiguous slices in the axial plane with the following param-
eters: TR 11.8 ms, TE 4.2 ms, flip angle 15°, FOV 30 cm, with a 
256 × 256 pixel matrix and a slice thickness of 1.2 mm.
Image preprocessing
Standard image preprocessing was conducted using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm) and the CONN-fMRI 
Functional Connectivity toolbox version 1320 with MATLAB 
version R2012b. All functional images were slice time– 
corrected, motion-corrected using a 6-parameter rigid body 
transformation, and then coregistered to each participant’s 
T1-weighted structural image. Coregistered images were nor-
malized to the Montreal Neurological Institute (MNI) canon-
ical template and smoothed with an 8 mm full-width at half-
maximum Gaussian kernel. Preprocessing procedures also 
included band-pass filtering with a frequency window of 
0.01–0.09 Hz and outlier detection using Artifact Detection 
Tools implemented in CONN. The principal component-
based noise-correction “CompCor” method was imple-
mented with this toolbox21 to additionally control for physio-
logic noise and head motion artifacts. Within each 
participant, volumes having large spiking (i.e., > 3 standard 
deviations from the mean image intensity) or large motion 
artifacts (i.e., 0.5 mm for scan-to-scan head motion composite 
changes in the x, y, or z direction) were classified as outliers.
Anatomic images were segmented into grey matter, white 
matter and cerebrospinal fluid (CSF) regions. Head motion 
(6 realignment parameters and their derivatives), outlier clas-
sification, and the blood oxygen level–dependent (BOLD) 
time series from the participant-specific white matter and 
CSF masks were used as nuisance regressors and removed 
from the BOLD functional time series using linear regression 
at the individual participant level. No participants had head 
movement exceeding ± 3 mm or more than 20% of the data 
points classified as outliers.
Functional connectivity analyses
Following preprocessing, we performed rs-fc analyses using 
the following regions of interest (ROIs) bilaterally: the BLA, 
CMA, vmPFC and ACC. Amygdala subregions of interest 
(BLA and CMA) were derived from the Juelich Histological 
Atlas22 with 6935 voxels in each side of the BLA and 2878 vox-
els in each side of the CMA after normalization to a standard 
template (2 × 2 × 2). Cortical ROIs (the vmPFC and ACC) 
were derived from the FSL Harvard–Oxford atlas maximum 
likelihood cortical atlas with a 70% threshold.23 Figure  1 
shows the ROIs used in the present study. As seen in the fig-
ure, the vmPFC included the medial orbitofrontal cortex, but 
excluded the subgenual region. The mean BOLD time series 
was computed across all voxels within each ROI, and Pearson 
correlation coefficients were calculated to determine the linear 
association of the BOLD time series between each pair of re-
gions for each participant. The resulting correlation coeffi-
cients were transformed into z-scores using  Fisher transfor-
mation to satisfy normality assumptions. These rs-fc values 
for each participant were then used in our group analyses.
Cognitive behavioural therapy and assessment of outcome
Cognitive behavioural therapy focused on exposure and 
ritual prevention, was manualized24 and provided by an 
experienced therapist who was blind to the study’s hy-
potheses. All patients received 20 individual weekly ses-
sions lasting approximately 45 minutes each. The first 
2 sessions were devoted to psychoeducation, the introduc-
tion to the behavioural model of OCD and the develop-
ment of an exposure hier archy. Sessions 3–18 consisted of 
gradual exposure to items of the hierarchy, during which 
patients faced their obsessional fears for a prolonged 
 period without ritualizing. The goal was for patients to 
stop their rituals as early as possible during treatment. 
Formal cognitive therapy techniques were not used, but 
dysfunctional cognitions were discussed within the con-
text of exposure. Between sessions, homework (60 minutes 
daily) consisting of exposure to stimuli similar to those ad-
dressed in the sessions was assigned. The final 2 sessions 
Fig. 1: Regions of interest used in the study. ACC = anterior cingulate cortex; BLA = basolateral amygdala; CMA = cen-
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were devoted to relapse prevention. The SSRI medication 
was kept at a stable dose throughout the study.
Clinicians not involved in treatment assessed OCD symp-
toms and comorbid depressive symptoms before and after 
CBT using the YBOCS25 and the Hamilton Rating Scale for 
Depression (HAMD).26 We operationalized CBT outcome 
both as a categorical (i.e., response v. nonresponse to CBT 
based on ≥ 35% decrease in the YBOCS total score)15 and a 
continuous (post-CBT YBOCS total score) variable.
Statistical analyses
To test our a priori hypothesis that BLA–vmPFC rs-fc 
would predict CBT outcome in patients with OCD, our 
primary analy ses consisted of a binomial logistic regres-
sion analysis with CBT response (yes v. no) as the de-
pend ent variable as well as a multiple regression analysis 
with post-CBT YBOCS as the dependent variable. In both 
the regression and the  logistic regression analyses, BLA–
vmPFC rs-fc was the predictor, and we adjusted for age, 
sex, OCD symptoms (baseline YBOCS) and depressive 
symptoms (baseline HAMD) as, based on previous re-
search,27 these covariates may be associated with CBT out-
come. Adjusting for these variables also reduces noise in 
the regression models, thereby increasing statistical 
power. In exploratory analyses, we tested the specificity 
of these results by repeating the same analyses  using 
CMA–vmPFC and BLA–ACC rs-fc. Finally, we explored 
differences in BLA–vmPFC rs-fc across patients with OCD 
and healthy controls using 1-way analysis of covariance 
(ANCOVA), adjusting for age and sex. We report findings 
from the 2 primary analyses that were significant after 
 Bonferroni correction and exploratory findings that were 
significant after Benjamini–Hochberg correction for pre-
serving the false-discovery rate.
Results
Participants
Of the initial sample of 83 eligible patients with OCD, 3 re-
fused to initiate CBT and 6 dropped out before completing 
the first 5 sessions. In addition, 1 patient and 2 of the 86 re-
cruited healthy controls were excluded for technical reasons 
(corrupted data), leaving 73 patients and 84 controls for 
analy sis. The demographic and clinical characteristics of the 
sample are shown in Table 1.
Response to CBT
After their completion of CBT, we considered 35 (48%) patients 
with OCD to be responders and 38 (52%) to be non responders. 
Responders and nonresponders did not differ significantly on 
any sociodemographic or clinical variables (including the fre-
quencies of type and dose of SSRI treatment; Appendix 1, 
Table S1, available at jpn.ca/160215-a1) other than baseline 
YBOCS score, which was lower in CBT responders than in non-
responders (mean 20.43 ± 4.88 v. 23.68 ± 4.81, t71 = 2.86, p = 0.005).
Does BLA–vmPFC rs-fc predict CBT outcome in patients 
with OCD?
Our binomial logistic regression model with CBT re-
sponse (yes v. no) as the dependent variable was statis-
tically sig nificant (χ2 = 16.246, p = 0.003). Decreased 
BLA–vmPFC rs-fc significantly predicted a better CBT 
outcome (odds ratio [OR] 0.032, Wald test = 5.246, p = 
0.022, Bonferroni-adjusted p = 0.044). Our multiple re-
gression model with YBOCS score following CBT as the 
dependent variable was also statistically significant 
(F5,67  = 28.193, p < 0.001, adjusted R2 = 0.654). Again, de-
creased BLA–vmPFC rs-fc predicted a better CBT out-
come (B = 7.42, t = 3.095, p = 0.003, Bonferroni-adjusted 
p = 0.006, Table 2). The same findings emerged when we 
used the difference between pre- and post-CBT YBOCS 
scores as the dependent variable, either controlling or not 
controlling for pre-CBT YBOCS (p = 0.003). Of note, BLA–
vmPFC rs-fc was not associated with baseline OCD 
 severity (pre-CBT YBOCS score: r = 0.068, p = 0.57) or ill-
ness duration (r = –0.016, p = 0.89).
Table 1: Sociodemographic and clinical characteristics of study 
participants
Group; mean ± SD or no. (%)
Characteristic OCD, n = 73 Control, n = 84
Mean age, yr 34.18 ± 9.25 33.68 ± 9.77
Mean age at OCD onset, yr 21.70 ± 7.50 —
Mean duration of education, yr 12.4 ± 3.05 12.2 ± 3.1
Male sex 35 (47.9) 41 (48.8)
Comorbidity
Affective disorders 12 (16.4) —
Major depressive disorder 5 (6.8) —
Dysthymia 4 (5.5) —
Depressive disorder NOS 3 (4.1) —
Anxiety disorders 9 (12.3) —
Social phobia 4 (5.5) —
Panic disorder 3 (4.1) —
Generalized anxiety disorder 2 (2.7) —
Tic disorders 7 (9.6) —
Baseline HAMD score 8.99 ± 3.72 —
HAMD score after 7.22 ± 3.73 —
Baseline YBOCS score 22.12 ± 5.08 —
YBOCS after CBT 15.37 ± 6.70 —
Pharmacological treatment† 73 (100) —
Fluoxetine, 60–80 mg/d 36 (49.3) —
Fluvoxamine, 200–300 mg/d 16 (21.9) —
Escitalopram, 20–40 mg/d 10 (13.7) —
Clomipramine, 225–300 mg/d 11 (15.1) —
Hypnotic benzodiazepines 24 (32.9) —
CBT = cognitive behavioural therapy; HAMD = Hamilton Rating Scale for Depression; 
NOS = not otherwise specified; OCD = obsessive–compulsive disorder; SD = standard 
deviation; YBOCS = Yale–Brown Obsessive Compulsive Scale. 
*Unless indicated otherwise.
†At least 12 weeks at this dose was required before scanning and initiating CBT. 
Medication was kept at a stable dose throughout the study.
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Are these findings specific to BLA–vmPFC rs-fc?
Neither CMA–vmPFC rs-fc nor BLA–ACC rs-fc significantly 
predicted CBT outcome using our categorical (yes v. no) 
outcome measure (CMA–vmPFC rs-fc: OR 0.065, Wald test 
= 1.956, p = 0.16,  Benjamini–Hochberg-adjusted p = 0.26; 
BLA–ACC rs-fc: OR 1.777, Wald test = 0.151, p = 0.70, 
 Benjamini–Hochberg-adjusted p = 0.80). Using our continu-
ous (post-CBT YBOCS score) measure as outcome, CMA–
vmPFC rs-fc was a significant predictor (B = 8.489, t = 2.518, 
p = 0.014,  Benjamini–Hochberg- adjusted p = 0.028), but 
BLA–ACC rs-fc was not (B = –0.362, t  = –0.131, p = 0.90, 
Benjamini–Hochberg-adjusted p = 0.90; Appendix 1, Tables 
S2 and S3).
Does BLA–vmPFC rs-fc differ between patients with OCD 
and healthy controls?
The results of our ANCOVA showed that BLA–vmPFC rs-fc 
differed significantly between patients with OCD and 
healthy controls (F1,153 = 9.676, p = 0.002, Benjamini–Hochberg-
adjusted p = 0.005, partial η2 = 0.05), with decreased BLA–
vmPFC rs-fc in the OCD group (mean difference = –0.103, 
95% confidence interval [CI] –0.169 to –0.038, p = 0.002, 
Benjamini–Hochberg-adjusted p = 0.005).
To examine whether decreased BLA–vmPFC rs-fc charac-
terized OCD per se or whether it decreased CBT response 
capacity, we conducted an additional ANCOVA comparing 
BLA–vmPFC rs-fc in CBT responders, CBT nonresponders 
and healthy controls, also adjusting for age and sex. This 
analysis revealed a main effect of group (F2,152 = 6.895, p = 
0.001, Benjamini–Hochberg-adjusted p = 0.005, partial η2 = 
0.08. Post hoc comparisons revealed significantly decreased 
BLA–vmPFC rs-fc in CBT responders compared with 
healthy controls (mean difference –0.153, 95% CI –0.235 to 
–0.071, Fisher least significance difference [LSD] p < 0.001) 
and CBT nonresponders (mean difference –0.096, 95% CI 
–0.191 to –0.0002, Fisher LSD p = 0.049). Additionally, BLA–
vmPFC rs-fc was similar across CBT nonresponders and 
healthy controls (mean difference –0.057, 95% CI –0.137 to 
–0.022,  Fisher LSD p = 0.16). Thus, decreased BLA–vmPFC 
rs-fc was uniquely characteristic of participants with OCD 
who responded to CBT (Fig. 2), consistent with our finding 
that BLA–vmPFC rs-fc was not significantly associated with 
baseline OCD severity.
Discussion
We investigated rs-fc between the amygdala and prefron-
tal cortex subregions in a large sample of patients with 
OCD and healthy participants. Our hypothesis was con-
firmed: BLA–vmPFC connectivity was significantly associ-
ated with CBT outcome, with decreased connectivity pre-
dicting a better outcome. These findings were relatively 
specific to BLA–vmPFC connectivity in that they were not 
replicated with measures of BLA–ACC (for either outcome 
measures) and were only replicated with CMA–vmPFC 
connectivity when our continuous outcome measure was 
used. Decreased BLA–vmPFC connectivity also character-
ized patients with OCD in comparison to healthy partici-
pants, but was specific to the patients with OCD who re-
sponded to CBT.
Table 2: Regression models predicting CBT outcome in patients with OCD (n = 73) with basolateral amygdala–ventromedial prefrontal cortex 
resting-state functional connectivity as a predictor
Binomial logistic regression model: CBT response (yes v. no) Multiple regression model: post-CBT YBOCS
Predictor Wald test OR* (95% CI) p value B  t (95% CI) p value
Sex 2.566 1.197 (0.961 to 1.491) 0.11 -0.413 –2.109 (–0.799 to –0.022) 0.039
Age 1.111 1.007 (0.994 to 1.020) 0.29 -0.008 –0.691 (–0.031 to –0.015) 0.49
Baseline YBOCS 
score
5.407 0.968 (0.942 to –0.995) 0.020 0.212 9.119 (0.166 to –0.251) < 0.001
Baseline HAMD score 0.29 0.997 (0.962 to 1.034) 0.87 0.001 0.023 (–0.063 to –0.065) 0.98
BLA–vmPFC rs-fc 5.246 0.494 (0.280 to –0.903) 0.022 1.524 3.095 (0.541 to 2.507) 0.003
BLA–vmPFC rs-fc = basolateral amygdala–ventromedial prefrontal cortex resting-state functional connectivity; CBT = cognitive behavioural therapy; CI = confidence interval;  
HAMD = Hamilton Rating Scale for Depression; OCD = obsessive–compulsive disorder; OR = odds ratio; YBOCS = Yale–Brown Obsessive Compulsive Scale.
*OR and multiple regression coefficients are reported for one standard deviation increase in the predictor.
Fig. 2: Mean values of resting-state functional connectivity (rs-fc)
between the basolateral amygdala and ventromedial prefrontal cor-
tex (BLA–vmPFC) in patients with obsessive–compulsive disorder 
(OCD) who responded to cognitive behavioural therapy (CBT; n = 
35), patients with OCD who did not respond to CBT (n = 38) and 
healthy controls (n = 84). Responders to CBT showed significantly 
decreased BLA–vmPFC rs-fc in comparison to healthy controls (p < 
0.001) and CBT nonresponders (p = 0.05). Bars represent standard 
error of the mean.
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Our finding that BLA–vmPFC functional connectivity is as-
sociated with CBT outcome is consistent with previous find-
ings showing associations of BLA degree centrality with CBT 
outcome in a much smaller sample of patients with OCD13 
and of amygdala–prefrontal functional connectivity with 
CBT outcome in patients with SAD (although in the opposite 
direction).14 Our results add specificity to these previous find-
ings, showing that BLA–vmPFC connectivity best predicts 
CBT outcome, rather than “overall” connectivity of the BLA, 
as measured by the degree centrality, or connectivity of the 
entire amygdala.
Although our comparison between patients and controls 
suggests that BLA–vmPFC functional connectivity may be 
abnormal in patients with OCD, as previously shown in 
other fear-related disorders,28 our comparison among CBT 
 responders, nonresponders and controls indicated that base-
line BLA–vmPFC connectivity may differ within patients 
with OCD who do or do not respond to CBT. Moreover, in 
our study, BLA–vmPFC connectivity was not associated with 
baseline OCD severity, suggesting that BLA–vmPFC connec-
tivity is a biomarker of responsivity to CBT rather than a 
marker of OCD psychopathology. Consistent with findings 
from the above-mentioned SAD study, these data suggest 
that measures of amygdala–prefrontal connectivity may pre-
dict CBT outcome across different fear-related disorders. Of 
note, amygdala–prefrontal connectivity was positively asso-
ciated with CBT outcome in patients with SAD,14 but in-
versely associated with outcome in patients with OCD.
Our findings suggest that CBT may have a restoring effect 
on the cortical inhibition of limbic activity. This interpretation 
is consistent with findings from task-based fMRI studies of 
depression in which participants with the least pretreatment 
subgenual ACC activation showed a better outcome with 
CBT,29,30 suggesting that CBT may be more helpful to those 
patients who cannot (at baseline) effectively engage brain 
 areas supporting emotional regulation. Similarly, our find-
ings suggest that patients with OCD with less cortical inhib-
ition (of the vmPFC over the BLA) at baseline might benefit 
most from the putative restoring effects of CBT.
Our interpretation of BLA–vmPFC functional connectivity 
as a marker of responsivity to CBT is consistent with the well-
established role of this circuit in adaptive learning.12 What is 
unclear, however, is how this circuit mediates CBT outcome. 
One possible explanation is that BLA–vmPFC connectivity 
represents an indirect measure of individual differences in fear 
extinction capacities. This explanation is consistent with recent 
findings that brain metabolism in the amygdala (as measured 
with FDG-PET) predicts fMRI activation of the vmPFC during 
fear extinction.31 Moreover, the better predictive value of BLA–
vmPFC over CMA–vmPFC in our study is consistent with ani-
mal and human data suggesting the pre-eminent role of the 
BLA in fear extinction learning.12,32 The association of CMA–
vmPFC connectivity with our continuous measure of CBT out-
come could reflect the association of CMA with fear extinction 
expression.33 However, amygdala–prefrontal circuits are in-
volved in other processes, such as attentional regulation and 
the interpretation of emotional stimuli,34 and these processes 
may also be associated with CBT response.
Our previous finding that less cortical thickness in the ros-
tral ACC was inversely associated with CBT outcome in this 
same sample19 suggests that cortical regions from the 
 ventral–anterior medial wall play an important role in pre-
dicting CBT, which can be apparent using different neuro-
imaging measures. It is possible that these measures index 
different aspects (e.g., attentional v. cognitive) of the same 
process (fear extinction).
The main implication of our findings is that examining the 
BLA–vmPFC circuit may offer important insights in the pre-
diction of CBT outcome for patients with OCD and, poten-
tially, patients with other fear-related disorders. Moreover, 
as baseline OCD severity was unassociated with BLA–
vmPFC connectivity and was controlled for in our analyses, 
our findings further suggest that such corticolimbic connec-
tivity may account for variability in CBT outcome beyond 
OCD baseline severity. Functional connectivity is relatively 
easy to acquire, has relatively high test–retest reliability35 
and does not rely on a patient’s ability to perform a task, 
which may favour its translation to the clinic. Strengths of 
this study include our clear hypothesis-driven approach 
based on previous translational research, the large sample of 
patients and controls and our analysis of specificity.
Limitations
A few limitations should be noted. First, we used a sample 
of convenience and did not include a control group of pa-
tients who were not receiving treatment. Thus, what is un-
known is whether our findings are specific to CBT or 
whether they also extend to other psychological treat-
ments. Second, we did not assess posttreatment changes in 
rs-fc, thereby precluding our understanding of functional 
connectivity changes associated with treatment. Third, all 
patients were receiving pharmacological treatment (SSRIs) 
for OCD. Patients who remained symptomatic following 
drug treatment were included in this study because most 
patients with OCD are unlikely to receive CBT as the first 
treatment option,36 making our administration of CBT in 
this study akin to real clinical practice and consistent with 
the use of CBT as an augmentation to drug treatment in 
nonresponders or partial responders.16 Although the po-
tential influence of medication on our results cannot be 
ruled out, medication effects would be similar across re-
sponders and nonresponders as both groups had almost 
identical pharmacological treatments. Other limitations 
 include our use of a 1.5 T scanner and a relatively short 
 resting-state scanning time. Although a 1.5 T scanner is 
 adequate for fMRI37 and for visualizing amygdala sub-
regions (e.g., see the study by Vogel and colleagues38), this 
study warrants replication at higher resolution and with 
longer scan durations. Moreover, although the study ther-
apists were highly experienced and followed a treatment 
manual, we did not evaluate fidelity to the manual or as-
sess treatment compliance among patients. Finally, we did 
not assess specific OCD symptom dimensions, which have 
been shown to modulate brain findings and treatment out-
come in some studies.39
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Conclusion
Our data suggest that a translationally guided and rela-
tively easy to collect neuroimaging assessment can be a sig-
nificant, relatively specific and clinically useful predictor of 
CBT outcome in patients with OCD. Future studies should 
test the predictive capacity of the same measure used here 
in unmedi cated patients and test the specificity of the find-
ings in patients with other disorders in which CBT is used 
and who are receiving other treatments (e.g., medication or 
non-CBT-based psychological treatments). If confirmed, the 
findings from our study could ultimately contribute to 
more personalized therapies for patients with OCD. On a 
broader level, they could help match treatments that rely 
on basolateral amygdala–ventromedial prefrontal path-
ways to those patients who will be most likely to benefit 
from them.
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